Terns Pharmaceuticals (TERN) Competitors $5.05 -0.06 (-1.17%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.08 +0.03 (+0.50%) As of 07/15/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock TERN vs. BHVN, EVO, ETNB, JANX, ANIP, EWTX, MESO, TVTX, CVAC, and CALTShould you be buying Terns Pharmaceuticals stock or one of its competitors? The main competitors of Terns Pharmaceuticals include Biohaven (BHVN), Evotec (EVO), 89BIO (ETNB), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Edgewise Therapeutics (EWTX), Mesoblast (MESO), Travere Therapeutics (TVTX), CureVac (CVAC), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Terns Pharmaceuticals vs. Its Competitors Biohaven Evotec 89BIO Janux Therapeutics ANI Pharmaceuticals Edgewise Therapeutics Mesoblast Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Biohaven (NYSE:BHVN) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Is BHVN or TERN more profitable? Terns Pharmaceuticals' return on equity of -28.81% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets BiohavenN/A -257.07% -164.01% Terns Pharmaceuticals N/A -28.81%-27.55% Do analysts prefer BHVN or TERN? Biohaven currently has a consensus price target of $58.46, indicating a potential upside of 340.45%. Terns Pharmaceuticals has a consensus price target of $15.63, indicating a potential upside of 209.41%. Given Biohaven's stronger consensus rating and higher probable upside, equities research analysts clearly believe Biohaven is more favorable than Terns Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Does the media refer more to BHVN or TERN? In the previous week, Biohaven had 7 more articles in the media than Terns Pharmaceuticals. MarketBeat recorded 10 mentions for Biohaven and 3 mentions for Terns Pharmaceuticals. Terns Pharmaceuticals' average media sentiment score of 0.62 beat Biohaven's score of 0.31 indicating that Terns Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biohaven 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Terns Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, BHVN or TERN? Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiohavenN/AN/A-$846.42M-$9.36-1.42Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-4.63 Do insiders & institutionals hold more shares of BHVN or TERN? 88.8% of Biohaven shares are owned by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are owned by institutional investors. 14.6% of Biohaven shares are owned by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, BHVN or TERN? Biohaven has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the S&P 500. SummaryBiohaven beats Terns Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Terns Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TERN vs. The Competition Export to ExcelMetricTerns PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$446.29M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-4.6320.2228.5719.58Price / SalesN/A289.98423.3593.43Price / CashN/A43.1536.0257.93Price / Book1.247.568.135.54Net Income-$88.85M-$55.11M$3.24B$257.73M7 Day Performance3.27%3.81%0.16%-0.08%1 Month Performance25.94%11.60%5.95%8.09%1 Year Performance-47.94%-2.11%26.09%13.02% Terns Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TERNTerns Pharmaceuticals3.8243 of 5 stars$5.05-1.2%$15.63+209.4%-49.4%$446.29MN/A-4.6340BHVNBiohaven3.3511 of 5 stars$13.81-5.6%$58.46+323.3%-65.5%$1.49BN/A-1.48239News CoverageEVOEvotec1.9817 of 5 stars$4.18-0.5%$5.93+41.9%-13.8%$1.49B$862.40M0.004,827Gap UpETNB89BIO2.0755 of 5 stars$10.22+0.6%$26.43+158.6%+16.8%$1.48BN/A-3.0240Analyst ForecastJANXJanux Therapeutics2.53 of 5 stars$23.96-2.0%$95.25+297.5%-40.7%$1.45B$9.34M-17.6230ANIPANI Pharmaceuticals3.7102 of 5 stars$64.91-0.6%$80.13+23.4%+1.2%$1.41B$614.38M-51.11600News CoverageAnalyst RevisionEWTXEdgewise Therapeutics1.4582 of 5 stars$12.61-3.2%$40.00+217.2%-41.5%$1.37BN/A-8.1460MESOMesoblast2.3709 of 5 stars$10.53-1.4%$18.00+70.9%+43.3%$1.36B$5.90M0.0080Positive NewsTVTXTravere Therapeutics3.7949 of 5 stars$14.60-2.7%$32.14+120.2%+67.0%$1.33B$233.18M-5.20460CVACCureVac4.7248 of 5 stars$5.41-0.7%$6.83+26.3%+50.3%$1.22B$579.18M5.88880Positive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies Biohaven Competitors Evotec Competitors 89BIO Competitors Janux Therapeutics Competitors ANI Pharmaceuticals Competitors Edgewise Therapeutics Competitors Mesoblast Competitors Travere Therapeutics Competitors CureVac Competitors Calliditas Therapeutics AB (publ) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TERN) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Terns Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Terns Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TERN Stock Alerts